Likewise, the LEADER trial concluded that a related GLP‐1 mimetic, namely, liraglutide, was beneficial in reducing the rate of non‐fatal myocardial infarction, stroke and first occurrence of death from cardiovascular causes (Marso, Daniels, et al., 2016). Here, GLP1R is linked to stroke disorder.